{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:40:43Z","timestamp":1787316043036,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality worldwide. Acute exacerbations are associated with progressive decline in lung function and quality of life. After recognition of the role of type 2 inflammation in the pathogenesis of eosinophilic COPD, there was increased interest in studying monoclonal antibodies as a therapeutic agent. Multiple randomized controlled trials showed promising results, yet no consensus exists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our study aims to summarize the current evidence regarding the role of monoclonal antibodies in the management of patients with eosinophilic COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched multiple databases using prespecified search terms. We included only randomized controlled trials that compared monoclonal antibodies versus placebo in patients with objective evidence of eosinophilic COPD receiving standard-of-care therapy. The primary outcome of interest was the annualized rate of COPD exacerbation. Absolute changes in forced expiratory volume in 1 second and St. George\u2019s Respiratory Questionnaire scores were secondary outcomes. We also reported serious adverse effects and all-cause mortality. Statistical analysis was conducted via random effects model using RevMan software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified and included eight double blinded, placebo-controlled trials with a total of 4,512 patients and a median follow up of 52 weeks. The patients\u2019 mean age was 65\u2009\u00b1\u20098 years, with 85% male. Seventy percent of patients were former smokers, with a mean of 43\u2009\u00b1\u200925 pack-years of smoking history. The majority of patients were receiving triple inhaled therapy. The mean serum eosinophil count at enrollment was 398\u2009\u00b1\u2009297 cells\/\u03bcl. The monoclonal antibodies studied were dupilumab, mepolizumab, benralizumab, astegolimab, and itepekimab. Compared with placebo, patients who received monoclonal antibodies had a significantly decreased annualized COPD exacerbation rate (rate ratio, 0.79; 95% confidence interval [CI], 0.73\u20130.86; P\u2009&amp;lt;\u20090.001). The serious adverse effect rate was significantly lower in the monoclonal antibody arm compared with placebo (odds ratio, 0.80; 95% CI, 0.69\u20130.93; P\u2009=\u20090.004). The all-cause mortality rates were not statistically different between the groups (odds ratio, 0.91; 95% CI, 0.63\u20131.3; P\u2009=\u20090.6). Dupilumab showed a trend of improved efficacy over mepolizumab and benralizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with eosinophilic COPD receiving standard-of-care therapy, the use of monoclonal antibodies led to a significant reduction in annualized COPD exacerbation rate compared with placebo. Monoclonal antibodies have an acceptable tolerability and safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202406-597oc","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T14:07:21Z","timestamp":1732630041000},"page":"768-775","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":12,"title":["Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-7811","authenticated-orcid":false,"given":"Mohamed M. G.","family":"Mohamed","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Saint Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Kamel","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Saint Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-1505","authenticated-orcid":false,"given":"Edward","family":"Charbek","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Saint Louis University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"2026012203060960900_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/resp.12660","article-title":"Global burden of COPD","volume":"21","author":"L\u00f5pez-Campos","year":"2016","journal-title":"Respirology"},{"key":"2026012203060960900_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/COPD.S234942","article-title":"Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review","volume":"15","author":"Iheanacho","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012203060960900_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"key":"2026012203060960900_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203060960900_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for Chronic Obstructive lung disease 2023 report: GOLD Executive Summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203060960900_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.chest.2022.07.015","article-title":"Association of inhaled corticosteroids with all-cause mortality risk in patients with COPD: a meta-analysis of 60 randomized controlled trials","volume":"163","author":"Chen","year":"2023","journal-title":"Chest"},{"key":"2026012203060960900_bib7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/03007995.2023.2247969","article-title":"Mortality risk reduction with budesonide\/glycopyrrolate\/formoterol fumarate versus fluticasone furoate\/umeclidinium\/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT","volume":"39","author":"Stolz","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"2026012203060960900_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012203060960900_bib9","doi-asserted-by":"crossref","first-page":"1089710","DOI":"10.3389\/fimmu.2023.1089710","article-title":"The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"2026012203060960900_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent advances in severe asthma: from phenotypes to personalized medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest"},{"key":"2026012203060960900_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203060960900_bib12","doi-asserted-by":"crossref","first-page":"e09736","DOI":"10.1016\/j.heliyon.2022.e09736","article-title":"A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils","volume":"8","author":"Ohnishi","year":"2022","journal-title":"Heliyon"},{"key":"2026012203060960900_bib13","doi-asserted-by":"crossref","first-page":"1207641","DOI":"10.3389\/fimmu.2023.1207641","article-title":"Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives","volume":"14","author":"Plichta","year":"2023","journal-title":"Front Immunol"},{"key":"2026012203060960900_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJMe2305752","article-title":"Biologics for COPD\u2014finally here","volume":"389","author":"Agusti","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012203060960900_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026012203060960900_bib16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012203060960900_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203060960900_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012203060960900_bib19","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012203060960900_bib20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026012203060960900_bib21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012203060960900_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pupt.2018.03.004","article-title":"Emerging biological therapies for treating chronic obstructive pulmonary disease: a pairwise and network meta-analysis","volume":"50","author":"Rogliani","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2026012203060960900_bib23","first-page":"CD013432","article-title":"Anti-IL-5 therapies for chronic obstructive pulmonary disease","volume":"12","author":"Donovan","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012203060960900_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pulmoe.2019.11.002","article-title":"Monoclonal antibodies for chronic obstructive pulmonary disease","volume":"26","author":"Siafakas","year":"2020","journal-title":"Pulmonology"},{"key":"2026012203060960900_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"2026012203060960900_bib26","doi-asserted-by":"crossref","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012203060960900_bib27","doi-asserted-by":"crossref","first-page":"8702","DOI":"10.3390\/ijms24108702","article-title":"The role of IL-33\/ST2 in COPD and its future as an antibody therapy","volume":"24","author":"Riera-Mart\u00ednez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026012203060960900_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12931-020-01482-1","article-title":"Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"2026012203060960900_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203060960900_bib30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203060960900_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/5\/768\/66015594\/annalsats_22_5_768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/5\/768\/66015594\/annalsats_22_5_768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:06:17Z","timestamp":1769069177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/5\/768\/8380640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202406-597oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"2024-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}